Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: An actuating system for a window shade includes a fixed support shaft, a rotary drum pivotally connected with the support shaft and rotatable for winding or unwinding a shading structure, and a limiting mechanism at least partially disposed inside the rotary drum and including a threaded portion provided on the support shaft, a stop portion and a limiting part respectively adjacent to a first and a second end of the threaded portion, and a follower engaged with the threaded portion, the follower being rotationally coupled to the rotary drum and slidable relative to the rotary drum. The rotary drum is rotatable in a first direction to drive the follower to slide toward a first position for engagement with the limiting part, and in a second direction to drive the follower to slide toward a second position for engagement with the stop portion.

Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

Abstract: Synthesis of a sulfoxide-containing homobifunctional cysteine-reactive mass spectrometry-cleavable cross-linker for mapping intra-protein interactions in a protein and inter-protein interactions in a protein complex is provided. Methods for mapping intra-protein interactions in a protein and inter-protein interactions in a protein complex and cross-linking mass spectrometry for identifying one or more cross-linked peptides using the cross-linker are provided.

Abstract: An electronic device is disclosed in the present disclosure. The electronic device comprises a substrate, a first layer and a second layer. The first layer is disposed on the substrate, and the second layer is disposed on the substrate and surrounds the first layer. An interface between the first layer and the second layer forms a light guiding channel, thereby improving the intensity of a light received by an optical sensor.

Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

Abstract: A composition for administration to a subject is disclosed and the composition comprises a vaccine and plinabulin without or with an adjuvant to induce, enhance or boost humoral response. A method of treatment by administering a vaccine and plinabulin is disclosed. A method of enhancing an immune response to a vaccine in a subject by administering to the subject a vaccine and plinabulin is also disclosed. The vaccine and plinabulin can be administered concurrently or separately.

Abstract: Disclosed herein are plinabulin and its use for treating a cancer or tumor characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, comprising administering plinabulin to a subject in need thereof.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Plinabulin and one or more G-CSF drugs are used for treating a chemotherapy induced neutropenia, stimulating neutrophil survival, reducing bone pain induced by the G-CSF drug and alleviating immune suppression effect induced by the G-CSF drug. For example, docetaxel-induced neutropenia can be reduced by-co-administering plinabulin and one or more G-CSF compounds.

Abstract: The present invention discloses an apparatus and method capable of automatically identifying an obstacle in front of a mobile terminal, the apparatus comprising a transmitting module, a receiving module, and a controller MCU module. The transmitting module is in signal connection to the receiving module, the transmitting module and the receiving module are both in signal connection to the controller MCU module (STM32 series), and the controller MCU module is also in signal connection to a mobile terminal CPU. The present invention may automatically identify the road condition in front of the mobile terminal and may carry out a voice prompt in time.

Abstract: A window shade includes a reel coupled to a first control module and connected with a panel assembly, a lift actuator coupled to a second control module, and a switchable coupling mechanism. The panel assembly has an open state for light passage and a closed state blocking light passage. The first control module can drive the reel in rotation for winding and unwinding the panel assembly. The second control module can drive the lift actuator in rotation for switching the panel assembly to the open or closed state. The coupling mechanism has a coupling state in which it rotationally couples the lift actuator to the first control module, and an uncoupling state in which it rotationally uncouples the lift actuator from the first control module. The coupling mechanism is in the uncoupling state while the panel assembly is closed, and in the coupling state while the panel assembly is opened.

Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

Abstract: This invention provides a novel cancer treatment method in which plinabulin (1-butyl-dehydrophenylahistin or NPI-2358) and a taxane compound (such as docetaxel) are used in combination. Our study has shown that the optimum combination of injecting plinabulin after taxane compound has unexpected enhanced efficacy in large tumor populations in animal model and in NSCLC cancer patients compared to taxane compound treatment alone. In addition, this optimum combination can achieve unexpected safety effect in lowering unbearable side effects of taxane compound, including decreasing its neutropenia rates at all grades and decreasing G-CSF use in cancer patients.

Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.

Abstract: The present invention discloses an apparatus and method capable of automatically identifying an obstacle in front of a mobile terminal, the apparatus comprising a transmitting module, a receiving module, and a controller MCU module. The transmitting module is in signal connection to the receiving module, the transmitting module and the receiving module are both in signal connection to the controller MCU module (STM32 series), and the controller MCU module is also in signal connection to a mobile terminal CPU.

Abstract: Provided herein is synthesis of a novel acidic acid residue targeting sulfoxide-containing MS-cleavable homobifunctional cross-linker. The novel mass spectrometry-cleavable cross-linking agents can be used in mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes. Also disclosed herein are data based on the novel MS-cleavable homobifunctional cross-linker that are complimentary to amine-reactive sulfoxide-containing MS-cleavable reagents.